Literature DB >> 8924052

Calcium channel antagonists in the modern era of coronary thrombolysis: benefit or detriment?

J A Foley, R C Becker.   

Abstract

Calcium channel antagonists are among the world's most widely prescribed class of drugs and are used most often in patients with hypertension and coronary artery disease. However, in the recent past serious questions have been raised concerning their potentially detrimental effects. One area of considerable clinical importance that deserves close inspection is the role of calcium channel antagonists following coronary reperfusion. Specifically, is there benefit or detriment?

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8924052     DOI： 10.1007/bf00051103

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


  50 in total

1.  Platelet activation by emotional stress in patients with coronary artery disease.

Authors:  G Grignani; F Soffiantino; M Zucchella; L Pacchiarini; F Tacconi; E Bonomi; A Pastoris; A Sbaffi; P Fratino; L Tavazzi
Journal:  Circulation       Date:  1991-04       Impact factor: 29.690

Review 2.  Calcium antagonists in elderly and black hypertensive patients. Therapeutic controversies.

Authors:  W Zing; R K Ferguson; P H Vlasses
Journal:  Arch Intern Med       Date:  1991-11

Review 3.  Current status of calcium channel blockers.

Authors:  W H Frishman
Journal:  Curr Probl Cardiol       Date:  1994-11       Impact factor: 5.200

4.  Effects by nifedipine on thromboxane synthesis in vitro and in vivo.

Authors:  G Davì; S Novo; M Fiore; A Foderà; A Mattina; A Mazzola; A Strano
Journal:  Thromb Res       Date:  1982-12-15       Impact factor: 3.944

5.  Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians.

Authors:  P M Ridker; J E Manson; J E Buring; J E Muller; C H Hennekens
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

Review 6.  Calcium channel blockers in myocardial infarction.

Authors:  A E Skolnick; W H Frishman
Journal:  Arch Intern Med       Date:  1989-07

7.  Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.

Authors:  J B Moore; B L Fuller; R Falotico; E L Tolman
Journal:  Thromb Res       Date:  1985-11-01       Impact factor: 3.944

8.  Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression.

Authors:  P Hjemdahl; N A Chronos; D J Wilson; P Bouloux; A H Goodall
Journal:  Arterioscler Thromb       Date:  1994-01

9.  Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets.

Authors:  H Affolter; W P Burkard; A Pletscher
Journal:  Eur J Pharmacol       Date:  1985-01-22       Impact factor: 4.432

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.